Everardo Cobos to Female
This is a "connection" page, showing publications Everardo Cobos has written about Female.
Connection Strength
0.263
-
Farmand D, Valdez MC, Moosavi L, Cobos E. Locus Minoris Resistentiae: Two Cases of Malignant Metastasis and Review of Literature. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:2324709621997248.
Score: 0.042
-
Delgado BJ, Moosavi L, Rangel E, Stull W, Polineni RD, Chen J, Cobos E. An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female. J Investig Med High Impact Case Rep. 2019 Jan-Dec; 7:2324709619868255.
Score: 0.036
-
Moosavi L, D'Assumpcao C, Bowen J, Heidari A, Cobos E. Leptomeningeal Carcinomatosis From Carcinoma of Unknown Primary in a Young Patient: A Case Report and a Literature Review. J Investig Med High Impact Case Rep. 2019 Jan-Dec; 7:2324709619869380.
Score: 0.036
-
Moosavi L, Bowen J, Coleman J, Heidari A, Cobos E. Acute Myelogenous Leukemia With Trisomy 8 and Concomitant Acquired Factor VII Deficiency. J Investig Med High Impact Case Rep. 2019 Jan-Dec; 7:2324709619872657.
Score: 0.036
-
Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, Figueroa A, Aulakh A, Konala V, Verma R, Riaz J, Wade R, Saadeh C, Rahman RL, Pandey A, Radhi S, Nguyen DD, Jenkins M, Chiriva-Internati M, Cobos E. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol. 2014 Oct; 33(5):383-401.
Score: 0.026
-
Sharma R, Heidari A, Cobos E, Petersen G, Ramzan AA, Polineni RD. Two Cases of Pelvic Diffuse Large B-Cell Lymphoma. J Investig Med High Impact Case Rep. 2022 Jan-Dec; 10:23247096221089505.
Score: 0.011
-
Thomas JS, El-Khoueiry AB, Maurer BJ, Groshen S, Pinski JK, Cobos E, Gandara DR, Lenz HJ, Kang MH, Reynolds CP, Newman EM. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemother Pharmacol. 2021 04; 87(4):525-532.
Score: 0.010
-
Mirandola L, Figueroa JA, Phan TT, Grizzi F, Kim M, Rahman RL, Jenkins MR, Cobos E, Jumper C, Alalawi R, Chiriva-Internati M. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget. 2015 Feb 20; 6(5):2812-26.
Score: 0.007
-
Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol. 2014 Dec; 135(3):573-9.
Score: 0.007
-
Mirandola L, Nguyen DD, Rahman RL, Grizzi F, Yuefei Y, Figueroa JA, Jenkins MR, Cobos E, Chiriva-Internati M. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? Int Rev Immunol. 2014 Oct; 33(5):417-27.
Score: 0.007
-
Pandey A, Kurup A, Shrivastava A, Radhi S, Nguyen DD, Arentz C, D'Chuna N, Hardwick F, D'Souza MJ, Jenkins M, Grizzi F, Kast WM, Cobos E, Rahman R, Chiriva-Internati M, Chiaramonte R, Platonova N. Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol. 2012 Oct; 31(5):302-20.
Score: 0.006
-
Chiriva-Internati M, Pandey A, Saba R, Kim M, Saadeh C, Lukman T, Chiaramonte R, Jenkins M, Cobos E, Jumper C, Alalawi R. Cancer testis antigens: a novel target in lung cancer. Int Rev Immunol. 2012 Oct; 31(5):321-43.
Score: 0.006
-
Mirandola L, Yu Y, Jenkins MR, Chiaramonte R, Cobos E, John CM, Chiriva-Internati M. Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4. BMC Cancer. 2011 Sep 16; 11:394.
Score: 0.005
-
Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86.
Score: 0.005
-
Yu Y, Pilgrim P, Yan J, Zhou W, Jenkins M, Gagliano N, Bumm K, Cannon M, Milzani A, Dalle-Donne I, Kast WM, Cobos E, Chiriva-Internati M. Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med. 2008 Oct 05; 6:56.
Score: 0.004
-
Chiriva-Internati M, Weidanz JA, Yu Y, Frezza EE, Jenkins MR, Kennedy RC, Cobos E, Kast WM. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother. 2008 Oct; 31(8):693-703.
Score: 0.004
-
Chiriva-Internati M, Cobos E, Da Silva DM, Kast WM. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun. 2008 Apr 24; 8:8.
Score: 0.004
-
Chiriva-Internati M, Grizzi F, Weidanz JA, Ferrari R, Yuefei Y, Velez B, Shearer MH, Lowe DB, Frezza EE, Cobos E, Kast WM, Kennedy RC. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods. 2007 Apr 10; 321(1-2):86-93.
Score: 0.004
-
Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med. 2004 Feb; 98(2):173-7.
Score: 0.003